Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study

Lung Cancer

Volumn 95, Issue , 2016, Pages 39-43

  Wang, Qiushi ^a   Zhao, Lianhua ^a   Yang, Xin ^a   Wei, Shirong ^a   Zeng, Ying ^a   Mao, Chengyi ^a   Lin, Li ^a   Fu, Ping ^a   Lyu, Liang ^a   Li, Zengpeng ^a   Xiao, Hualiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

1A4; ALK; D5F3; FISH; Immunohistochemistry; Lung adenocarcinoma

Indexed keywords

1A4 ANTIBODY; ANAPLASTIC LYMPHOMA KINASE; CANCER ANTIBODY; D5F3 ANTIBODY; MICROTUBULE ASSOCIATED PROTEIN 4; UNCLASSIFIED DRUG; ANTIBODY; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; AUTOMATIC SLIDE STAINER; CANCER SCREENING; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; ADENOCARCINOMA; BIOPSY; CHINA; GENE REARRANGEMENT; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PROCEDURES; RISK FACTOR; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; BIOPSY; CHINA; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84959338148     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.02.014     Document Type: Article

References (26)

1. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
2. Gandhi Leena, Jänne Pasi A. Crizotinib for ALK-rearranged non-small cell lung Cancer: a new targeted therapy for a new target. Clin. Cancer Res. 2012, 18:3737-3742.
3. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Jänne P.A., Costa D.B., Varella-Garcia M., Kim W.H., Lynch T.J., Fidias P., Stubbs H., Engelman J.A., Sequist L.V., Tan W., Gandhi L., Mino-Kenudson M., Wei G.C., Shreeve S.M., Ratain M.J., Settleman J., Christensen J.G., Haber D.A., Wilner K., Salgia R., Shapiro G.I., Clark J.W., Iafrate A.J. Anaplastic lymphomakinase inhibition in non small cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
4. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., Riely G.J., Solomon B., Ou S.H., Kim D.W., Salgia R., Fidias P., Engelman J.A., Gandhi L., Jänne P.A., Costa D.B., Shapiro G.I., Lorusso P., Ruffner K., Stephenson P., Tang Y., Wilner K., Clark J.W., Shaw A.T. Activity and safety of crizotinibin patients with ALK positive non small cell lung cancer: updated resultsfrom a phase 1 study. Lancet Oncol. 2012, 13:1011-1019.
5. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., Wu Y.L., Thomas M., O'Byrne K.J., Moro-Sibilot D., Camidge D.R., Mok T., Hirsh V., Riely G.J., Iyer S., Tassell V., Polli A., Wilner K.D., Jänne P.A. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368:2385-2394.
6. Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., Iyer S., Reisman A., Wilner K.D., Tursi J., Blackhall F. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 371(23):2167-2177.
7. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., Solomon B., Stubbs H., Admane S., McDermott U., Settleman J., Kobayashi S., Mark E.J., Rodig S.J., Chirieac L.R., Kwak E.L., Lynch T.J., Iafrate A.J. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009, 27:4247-4253.
8. Teixido C., Karachaliou N., Peg V., Gimenez-Capitan A., Rosell R. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. Transl. Lung Cancer Res. 2014, 3(2):70-74.
9. Li Y., Pan Y., Wang R., Sun Y., Hu H., Shen X., Lu Y., Shen L., Zhu X., Chen H. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One 2013, 8:e69016.
10. Wynes M.W., Sholl L.M., Dietel M., Schuuring E., Tsao M.S., Yatabe Y., Tubbs R.R., Hirsch F.R. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J. Thorac. Oncol. 2014, 9(5):631-638.
11. Ying J., Guo L., Qiu T., Shan L., Ling Y., Liu X., Lu N. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann. Oncol. 2013, 24(10):2589-2593.
12. Martin V., Bernasconi B., Merlo E., Balzarini P., Vermi W., Riva A., Chiaravalli A.M., Frattini M., Sahnane N., Facchetti F., Mazzucchelli L., Sessa F., Tibiletti M.G. ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice. J. Thorac. Oncol. 2015, 10(4):595-602.
13. Cabillic F., Gros A., Dugay F., Begueret H., Mesturoux L., Chiforeanu D.C., Dufrenot L., Jauffret V., Dachary D., Corre R., Lespagnol A., Soler G., Dagher J., Catros V., Le Calve M., Merlio J.P., Belaud-Rotureau M.A. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J. Thorac. Oncol. 2014, 9(3):295-306.
14. McLeer-Florin A., Moro-Sibilot D., Melis A., Salameire D., Lefebvre C., Ceccaldi F., de Fraipont F., Brambilla E., Lantuejoul S. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routinepractice: a French study. J. Thorac. Oncol. 2012, 7:348-354.
15. Martelli M.P., Sozzi G., Hernandez L., Pettirossi V., Navarro A., Conte D., Gasparini P., Perrone F., Modena P., Pastorino U., Carbone A., Fabbri A., Sidoni A., Nakamura S., Gambacorta M., Fernández P.L., Ramirez J., Chan J.K., Grigioni W.F., Campo E., Pileri S.A., Falini B. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol. 2009, 174:661-670.
16. Fu S., Wang F., Shao Q., Zhang X., Duan L.P., Zhang X., Zhang L., Shao J.Y. Detection of EML4-ALK fusion gene in Chinese non-small cell lung cancer by using a sensitive quantitative real-time reverse transcriptase PCR technique. Appl. Immunohistochem. Mol. Morphol. 2015, 23(4):245-254.
17. Wang W., Tang Y., Li J., Jiang L., Jiang Y., Su X. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization. Cancer Cytopathol. 2015, 123(2):117-122.
18. Selinger C.I., Rogers T.M., Russell P.A., O'Toole S., Yip P., Wright G.M., Wainer Z., Horvath L.G., Boyer M., McCaughan B., Kohonen-Corish M.R., Fox S., Cooper W.A., Solomon B. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. 2013, 26(12):1545-1553.
19. Tuononen K., Sarhadi V.K., Wirtanen A., Rönty M., Salmenkivi K., Knuuttila A., Remes S., Telaranta-Keerie A.I., Bloor S., Ellonen P., Knuutila S. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. Biomed. Res. Int. 2013, 2013:757490.
20. Lazzari C., Spitaleri G., Catania C., Barberis M., Noberasco C., Santarpia M., Delmonte A., Toffalorio F., Conforti F., De Pas T.M. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options. Crit. Rev. Oncol. Hematol. 2014, 89(3):358-365.
21. Mino-Kenudson M., Chirieac L.R., Law K., Hornick J.L., Lindeman N., Mark E.J., Cohen D.W., Johnson B.E., Jänne P.A., Iafrate A.J., Rodig S.J. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin. Cancer Res. 2010, 16(5):1561-1571.
22. Conklin C.M., Craddock K.J., Have C., Laskin J., Couture C., Ionescu D.N. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J. Thorac. Oncol. 2013, 8(1):45-51.
23. Minca E.C., Portier B.P., Wang Z., Lanigan C., Farver C.F., Feng Y., Ma P.C., Arrossi V.A., Pennell N.A., Tubbs R.R. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J. Mol. Diagn. 2013, 15:341-346.
24. Savic S., Bode B., Diebold J., Tosoni I., Barascud A., Baschiera B., Grilli B., Herzog M., Obermann E., Bubendorf L. Detection of ALK-positive non- small-cell lung cancers oncytological specimens: high accuracy of immunocytochemistry with the 5A4 clone. J. Thorac. Oncol. 2013, 8:1004-1011.
25. Gruber K., Kohlhäufl M., Friedel G., Ott G., Kalla C. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry. J. Thorac. Oncol. 2015, 10(4):713-716.
26. Rodig S.J., Mino-Kenudson M., Dacic S., Yeap B.Y., Shaw A., Barletta J.A., Stubbs H., Law K., Lindeman N., Mark E., Janne P.A., Lynch T., Johnson B.E., Iafrate A.J., Chirieac L.R. Unique clinicopathologicfeatures characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 2009, 15:5216-5223.